Oncogenic and tumor-suppressive forces converge on a progenitor niche at the benign-to-malignant transition

Read full text
Authors: Jose Reyes, Isabella Del Priore, Andrea C. Chaikovsky, Nikhita Pasnuri, Ahmed M. Elhossiny, Jin Park, Philipp Weiler, Tobias Krause, Andrew Moorman, Catherine Snopkowski, Meril Takizawa, Cassandra Burdziak
+13 more Nalin Ratnayeke, Ignas Masilionis, Yu-Jui Ho, Ronan Chaligné, Paul B. Romesser, Aveline Filliol, Tal Nawy, John P. Morris, Zhen Zhao, Marina Pasca Di Magliano, Direna Alonso‐Curbelo, Dan Peer, S Lowe
Cited by: 5
References: 154

Abstract

The benign-to-malignant transition is a defining step in cancer progression. To investigate when and how malignancy initiation occurs and tissue reorganization proceeds, we combine single-cell and spatial transcriptomic profiling in mouse models of pancreatic ductal adenocarcinoma (PDAC) that capture spontaneous p53 loss. Among Kras-mutant cells, we find that oncogenic and tumor-suppressive programs, including those controlled by p53, CDKN2A, and SMAD4, are co-activated in a discrete progenitor-like population, engaging senescence-like responses. Using a framework we developed for spatial analysis, we show that a niche centered on these cells undergoes stepwise remodeling during tumor progression, mirroring invasive PDAC. Transient KRAS inhibition depletes progenitor-like cells and dismantles their niche, delaying malignancy initiation. Conversely, p53 suppression enables progenitor cell expansion, epithelial-mesenchymal reprogramming, and immune-privileged niche formation. These findings position the progenitor-like state at the convergence of cancer-driving mutations, plasticity, and tissue remodeling, revealing a critical window for intercepting malignancy.

Fields of Study & Subjects

Cancer Cells and Metastasis Cancer Genomics and Diagnostics Angiogenesis and VEGF in Cancer

Publication details

Journal / source
Cell
Publisher
Elsevier BV
Volume
189
Issue
10
Pages
2875–2897.e53
Publication date
15 April 2026
Language
EN